1-5 of 5
Christopher R. Bolen
Close
Sort by
Journal Articles

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Clinical Trials & Observations
Ann-Marie E. Bröske, Koorosh Korfi, Anton Belousov, Sabine Wilson, Chia-Huey Ooi, Christopher R. Bolen, Marta Canamero, Enrique Gomez Alcaide, Ian James, Emily C. Piccione, David J. Carlile, Natalie Dimier, Pablo Umaña, Marina Bacac, Martin Weisser, Michael Dickinson
Journal: Blood Advances
Blood Adv (2022) 6 (3): 1025–1037.
https://doi.org/10.1182/bloodadvances.2021005954
Published: 2022
Includes: Supplemental data
Journal Articles

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Clinical Trials & Observations
Jonathan C. Strefford, Malgorzata Nowicka, Chantal E. Hargreaves, Cathy Burton, Andrew Davies, Rosalind Ganderton, Wolfgang Hiddemann, Chisako Iriyama, Wolfram Klapper, Kate V. Latham, Maurizio Martelli, Farheen Mir, Helen Parker, Kathleen N. Potter, Matthew J. J. Rose-Zerilli, Laurie H. Sehn, Marek Trněný, Umberto Vitolo, Christopher R. Bolen, Christian Klein, Andrea Knapp, Mikkel Z. Oestergaard, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2935–2944.
https://doi.org/10.1182/bloodadvances.2020003985
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Clinical Trials & Observations
Malgorzata Nowicka, Laura K. Hilton, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter, Stephen A. Beers, Kathleen N. Potter, Christopher R. Bolen, Christian Klein, Andrea Knapp, Farheen Mir, Matthew Rose-Zerilli, Cathy Burton, Wolfram Klapper, David W. Scott, Laurie H. Sehn, Umberto Vitolo, Maurizio Martelli, Marek Trneny, Christopher K. Rushton, Graham W. Slack, Pedro Farinha, Jonathan C. Strefford, Mikkel Z. Oestergaard, Ryan D. Morin, Mark S. Cragg
Journal: Blood Advances
Blood Adv (2021) 5 (15): 2945–2957.
https://doi.org/10.1182/bloodadvances.2021004770
Published: 2021
Includes: Supplemental data
Journal Articles

PD-L1 and tumor-associated macrophages in de novo DLBCL

Clinical Trials & Observations
Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, Edward E. Kadel, III, Mikkel Z. Oestergaard, Tina Nielsen, Laurie H. Sehn, Jeffrey M. Venstrom
Journal: Blood Advances
Blood Adv (2019) 3 (4): 531–540.
https://doi.org/10.1182/bloodadvances.2018020602
Published: 2019
Includes: Supplemental data
Journal Articles

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets

Christopher R. Bolen, Ronald McCord, Sarah Huet, Garrett M. Frampton, Richard Bourgon, Fabrice Jardin, Peggy Dartigues, Elizabeth A. Punnoose, Edith Szafer-Glusman, Luc Xerri, Pierre Sujobert, Gilles Salles, Jeffrey M. Venstrom
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1884–1890.
https://doi.org/10.1182/bloodadvances.2016000786
Published: 2017
Includes: Supplemental data